Lp(a)HORIZON: What Pelacarsen’s Failure Really Teaches Us About Lipoprotein(a)
On September 4, 2026, Novartis announced the topline results of Lp(a)HORIZON, the largest cardiovascular outcomes trial ever run on lipoprotein(a), or Lp(a). Pelacarsen, an antisense drug built to switch off Lp(a) production in the liver, lowered Lp(a) levels as expected. But it did not cut the rate of heart attacks, strokes, cardiovascular death, or urgent…